Advertisement

Ophthalmology

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., and Ube Corp. have received FDA approval for their Omlonti 0.002 percent eye drops, which are designed to reduce elevated intraocular pressure in glaucoma patients. 

Advertisement

EyeSouth Partners will add 19 new physicians before the end of 2022 across 14 of its practices nationwide. 

Biotechnology company Provectus Biopharmaceuticals has entered into an option agreement with the University of Miami for the exclusive licensing of products developed by its Ophthalmic Biophysics Center of Bascom Palmer Eye Institute. 

Advertisement